Investor Relations
Bone Biologics is focused on advancing orthopedic care by accelerating healing and enhancing clinical outcomes in patients undergoing spine fusion and other bone-related conditions. We are exploring other applications with our NELL-1 technology to enhance bone regeneration and repair.
Value Proposition
Physicians & Healthcare Systems
- Reduced costs and improved clinical outcomes to drive utilization
- Promising treatment with fewer complications and reoperations
- Established market and reimbursement
Patients
- Enhanced clinical outcomes
- Targeted guided bone growth
- Improved fusions and healing
Management Team
Jeff Frelick
Chief Executive Officer | President
Jeff Frelick
Chief Executive Officer | President
Jeffrey Frelick assumed the CEO and President role in June 2019. Previously he served as the Chief Operating Officer of Bone Biologics Inc. since August 2015. Frelick brings more than 25 years of med-tech experience to the position. He spent the past 15 years on Wall Street as a sell-side analyst following the med-tech industry at investment banks such as Canaccord Genuity, ThinkEquity and Lazard. Prior to becoming an equity research analyst, Frelick worked at Boston Biomedical Consultants where he provided strategic planning assistance, market research data and due diligence for diagnostics companies. He previously held sales and sales management positions at Becton Dickinson’s Primary Care Diagnostic Division after gaining technical experience as a laboratory technologist with Clinical Pathology Facility. Frelick earned a B.S. in Biology from the University of Pittsburgh and an M.B.A. from Suffolk University’s Sawyer Business School.
Deina Walsh
Chief Financial Officer
Deina Walsh
Chief Financial Officer
Deina Walsh was appointed CFO of Bone Biologics in October 2014. Walsh is a certified public accountant and owner/founder of DHW CPA, PLLC a Public Companies Accounting Oversight Board (PCAOB) registered firm since 2014. Prior to forming her firm, Walsh spent 13 years at a public accounting firm where she was actively responsible for leading firm audit engagements of publicly held entities in accordance with PCAOB standards and compliance with SEC regulations, including internal control requirements under section 404 of the Sarbanes-Oxley Act. Her experience includes work with start-up companies and well-established operating entities. She has assisted many entities seeking debt and equity capital. Areas of specialty include mergers, acquisitions, reverse mergers, consolidations, complex equity structures, foreign currency translations and revenue recognition complexities. Walsh earned an A.S. in Business Administration from Monroe Community College and a B.S. in Accounting from the State University of New York at Brockport.
Brent Atkinson, Ph.D.
R&D Consultant
Brent Atkinson, Ph.D.
R&D Consultant
Dr. Atkinson has over 25 years of leading product development, clinical, and regulatory experience in the orthopedic industry. He was previously vice-president of R&D at AlloSource and vice-president of product development at BioSET. He also held roles of Director of R&D at Dentsply and product development scientist at Sulzer Biologics. Dr. Atkinson received his Ph.D. in molecular biology from Columbia University.
Board of Directors
Bruce Stroever, Chairman
Former CEO, Musculoskeletal Transplant Foundation
Bruce Stroever, Chairman
Former CEO, Musculoskeletal Transplant Foundation
Mr. Stroever has forty years of product development and general management experience in the medical device and orthobiologics fields. Mr. Stroever joined MTF in late 1988 as General Manager and retired in mid-2018 from his position as the President and Chief Executive Officer of MTF. He served as MTF’s President since his appointment in 1992 and as Chief Executive Officer since 1996. Under Mr. Stroever’s leadership, MTF grew to be the largest tissue bank in the world providing over 500,000 grafts per year with revenues over $400 million. From 1971 to 1988, Mr. Stroever held several positions with Ethicon, Inc., a Johnson & Johnson, Inc. subsidiary. Mr. Stroever currently serves on the advisory board for the New Jersey Organ and Tissue Sharing Network. He was elected to the Board of Governors of the American Association of Tissue Banks for a three year term in 1999 and subsequently in 2012. He was a founding member of the Tissue Policy Group subsidiary of the AATB and served as its Chairman for two terms. Mr. Stroever served as the Chairman of the Bone Biologics Board of Directors from 2012 through mid-2018. Mr. Stroever received his B.E. in Mechanical/Chemical Engineering from Stevens Institute of Technology in 1972 and a Masters of Science in Bioengineering from Columbia University in 1977.
Rob Gagnon
Chief Financial Officer Opus Genetics
Rob Gagnon
Chief Financial Officer Opus Genetics
Mr. Gagnon brings over 20 years of financial and operational experience in the biotechnology and medical device industries. He previously served as the Chief Financial Officer at Remix Therapeutics and as an operating partner at Gurnet Point Capital, CFO for Veratem Oncology as well as Harvard Biosciences. Earlier in his career Mr. Gagnon spent time at Deloitte & Touche and PricewaterhouseCoopers. Mr. Gagnon holds an MBA from MIT Sloan School of Management and a BA in accounting from Bentley College.
Siddhesh Angle, Ph.D.
President and CEO Regenosine
Siddhesh Angle, Ph.D.
President and CEO Regenosine
Dr. Angle has 15 years of musculoskeletal research and development experience. Previously he was the R&D Manager for Zimmer Global Biologics. Dr. Angle has worked at several start ups and successfully commercialized orthopedic medical devices and combination therapies. He holds an MS and Ph.D. from University of Illinois at Chicago.
Phillip Meikle
President and CEO Biosystems
Phillip Meikle
President and CEO Biosystems
Mr. Meikle is a seasoned healthcare executive with over 32 years of orthopedic and spine industry experience. He founded Biosystems of New England, Inc. in 1992 and has served as CEO and President since. He has broad experience representing diverse and innovative orthopedic industry companies in developing and distributing innovative products. He sold his company to Stryker in 2019 and has served as a Stryker consultant for the past five years.
Frequently Asked Questions
When was the company founded?
The Company was founded in 2004 in Los Angeles, CA
How can I obtain copies of Bone Biologic’s financial reports, or request an investor kit or annual report?
Financial reports are available in the “SEC Filings” page of the “Investors” section of the company’s website.
Where can I find Bone Biologics’ latest investor presentation?
The company’s most recent investor presentation is available on the “Investors” section on the company’s website.
Financial Reporting & Stock Information:
When is Bone Biologics’ fiscal year end?
The fiscal year ends on December 31.
Where is Bone Biologics stock traded?
Bone Biologics stock is traded on Nasdaq under the symbol “BBLG.”
Does Bone Biologics pay dividends on its common stock?
Bone Biologics has never declared or paid cash dividends. The company intends to retain any future earnings for the operation and expansion of its business and does not anticipate paying any cash dividends in the foreseeable future.
External Advisors and Contact Information:
Who are Bone Biologics’ independent auditors?
Weinberg & Company, P.A.
1925 Century Park East
Los Angeles, California
Who do I contact to request information on my account or change my account information?
Questions regarding stock holdings, certificate replacement/transfer and address changes should be directed to our Transfer Agent:
Equiniti Trust Company
Jeff Carlson
(651) 306 2920
[email protected]
1110 Centre Pointe Curve, Suite 101
Mendota Heights MN 55120
Who is Bone Biologics’ outside corporate counsel?
Harter Secrest & Emery LLP
1600 Bausch & Lomb Place
Rochester, NY 14604-2711
Morse Law
480 Totten Pond Rd
Waltham, MA 02451
How do I contact Bone Biologics Investor Relations?
CORE IR
Investor Relations
(212) 655-0924
[email protected]
Where are Bone Biologics headquarters?
Bone Biologics is headquartered in Burlington, Mass.